Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Regence BlueShieldAll Plans · Coverage · Coding · Gastroenterology, Internal MedicineMedium impact

Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease

Effective date
Oct 1, 2026
Identified
Sep 2, 2026

Summary

Multianalyte serum assays with algorithmic analysis, including HCV FibroSURE (FibroTest), Elasto-FibroTest, FIBROSpect II, ASH FibroSURE, NASH FibroSURE, LiverFASt, NIS2+ and OWLiver, are considered investigational for the evaluation and monitoring of patients with chronic liver disease. Contracts exclude investigational services from coverage, and providers may bill members for them. There is not enough research to know whether these assays improve health outcomes, and the policy does not address the Enhanced Liver Fibrosis (ELF) test.

Get alerts when payers change rules like this one

We check Regence BlueShield and other payers every day and email you when a change matches your specialty and state.

Get Regence BlueShield alertsPolicy Monitoring is free. No card required.

What to do

Action · 6 steps
01Already effective Oct.
021, 2026: The listed multianalyte assays are considered investigational for evaluating and monitoring chronic liver disease, and contracts exclude investigational services from coverage, so billing team should not expect coverage for these assays under the contract for these purposes.
03Before rendering these services, providers are encouraged to inform members that the members are likely to be financially responsible for the cost, since providers may bill members for services considered investigational.
04Before billing, check the applicable contract language, because contract language takes precedence over the medical policy.
05The policy does not address the Enhanced Liver Fibrosis (ELF) test.
06Future review: The next review of this policy is scheduled for May 2027.

Codes mentioned

8159681599835208388384999

Original notice

Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease
beonbrand.getbynder.com · Always check the source before changing claims.
View original ↗

Related changes

See all Regence BlueShield changes →
Investigational Gene Expression, Biomarker, and Multianalyte TestingMediumEffective Sep 1, 2026 · CodingInvestigational Gene Expression, Biomarker, and Multianalyte TestingMediumEffective Sep 1, 2026 · CodingEvaluating the Utility of Genetic PanelsMediumEffective Oct 1, 2026 · CodingBrowse every Regence BlueShield change in the policy list

Related policy hubs

Regence BlueShield policiesGastroenterologyInternal MedicineCode 81596Code 81599Code 83520Code 83883Code 84999

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account